XML 55 R42.htm IDEA: XBRL DOCUMENT v3.25.3
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 37 Months Ended 94 Months Ended
Dec. 31, 2017
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2025
USD ($)
product
milestone
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenues   $ 581,000 $ 49,412,000 $ 25,324,000 $ 50,249,000    
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Agreement termination, term (in years) 15 years            
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | Recognition of license revenue              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Milestone payments received $ 12,000,000           $ 5,000,000
Number of products approved | product             0
Number of milestones included in transaction price | milestone             0
Collaborative arrangement transaction price           $ 17,000,000  
Revenues   $ 0 $ 0 $ 0 $ 0    
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | Recognition of license revenue | Maximum              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Percentage of net sales per developed licensed product which will trigger royalties by counterparty (as a percent) 20.00%            
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | Recognition of license revenue | Maximum | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Development and sales-based milestone payments to be received $ 60,000,000            
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | Recognition of license revenue | Maximum | Achievement Of Commercial Milestones              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Development and sales-based milestone payments to be received $ 90,000,000            
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | Recognition of license revenue | Minimum              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Percentage of net sales per developed licensed product which will trigger royalties by counterparty (as a percent) 14.00%